AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control

RecruitingNAAges 18 Years - 80 YearsAllShanghai 6th People's Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. 18 years old โ‰ค age โ‰ค 80 years old. 2. Type 2 diabetes admitted to Department of Endocrinology and Metabolism. 3. 8% โ‰ค HbA1c โ‰ค 12% in the last 1 month. 4. Insulin therapy within 1 month of planned discharge from hospital. 5. Frequency of self-monitoring of blood glucose \<4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation. 6. Willing and able to provide written informed consent and comply with the requirements of this study. Exclusion Criteria: 1. Oral steroid hormone therapy. 2. Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis) 3. Patients with severe liver disease (alanine aminotransferase or glutamine aminotransferase exceeding more than three times the upper limit of normal). 4. Patients with severe kidney injury or end-stage renal disease (eGFR \< 30 mL/min/1.73 m2). 5. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area. 6. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 7. Pregnant, breastfeeding, women of childbearing age who are unwilling to use contraception during the study period.
๐Ÿ’Š

What it tests

  • RT-CGM
  • SMBG
๐Ÿ“

Where

1 site
Shanghai 6th People's Hospital
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy